Japan· JP-1233400A2016
ネオスチグミンメチル硫酸塩
A neostigmine product containing ネオスチグミンメチル硫酸塩, registered in Japan, on the national reimbursement list. The same ATC class is registered in 10 of our 19 countries.
Checked against MHLW / PMDA (Japan) on
Informational only — not a medical device.
Where it is registered
Neostigmine is registered in 10 of 19 countries.
Countries holding a registration under ATC N07AA01 (neostigmine), each read from that country’s own register.
- This record: Japan, from MHLW / PMDA (Japan)
- 6 of them publish a price we can compare per daily dose
Neostigmine · ATC N07AA01
10 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Finlandprice
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
The record
At a glance
MHLW / PMDA (Japan)- Active substance
- ネオスチグミンメチル硫酸塩
- Manufacturer
- —
- Country
- Japan (JP)
- ATC code
- N07AA01
- ATC class
- Neostigmine
- Defined daily dose
- 60 mg, O
- Reimbursed
- Yes
- Source register
- MHLW / PMDA (Japan)
- Last checked
- September 25, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
68 interactions on record for neostigmine.
Graded by severity as the source publishes them — 6 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Neostigmine · interactions on record
68 records
- 6 severe
- 62 moderate
Most severe, free to view
- SiponimodL04AA42severe
- SiponimodL04AE03severe
- BupropionN06AX12severe
- BupropionN07BA02severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Neostigmine in 4 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United KingdomNeostigmine 10mg/5ml oral solutionSpecial Order
- CzechiaSYNTOSTIGMINZentiva, k.s., Praha
- SpainNEOSTIGMINA BRAUN 0,5 MG/ML SOLUCIÓN INYECTABLEB Braun Medical S.A.
- FrancePROSTIGMINE 0,5 mg/1 ml, solution injectableVIATRIS MEDICAL
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Czechia · Syntostigmin
- Romania · Neostigmină Lph Labormed
- Slovakia · Syntostigmin
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of MHLW / PMDA (Japan). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/bf5775f9-6baa-47aa-a6ca-d62d03e45575 GET /v1/drugs/bf5775f9-6baa-47aa-a6ca-d62d03e45575?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"spec": "０．０５％１ｍＬ１管",
"marks": "局",
"source": "mhlw",
"remarks": null,
"yj_code": "1233400A2016",
"category": "注射薬",
"price_yen": null,
"generic_name": "ネオスチグミンメチル硫酸塩",
"product_name_jp": null,
"therapeutic_class": "1233",
"transitional_expiry": null
}See everything about neostigmine.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.